BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of Buy from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued a […]

Related Keywords

Canada ,United States ,America , ,Lazard Asset Management ,Analyst Recommendations For Biocryst Pharmaceuticals ,Biocryst Pharmaceuticals Stock Down ,Jefferies Financial Group ,Nasdaq ,Third Bancorp ,News Ratings For Biocryst Pharmaceuticals Daily ,Biocryst Pharmaceuticals ,Fairfield Bush ,Royal Bank ,Advisory Services Network ,Fifth Third Bancorp ,Biocryst Pharmaceuticals Company Profile ,Biocryst Pharmaceuticals Inc ,Needham Company ,Get Free Report ,Marketbeat Ratings ,Asset Management ,Services Network ,Cryst Pharmaceuticals Stock Down ,Get Free ,Cryst Pharmaceuticals ,Biocryst Pharmaceuticals Daily ,Nasdaq Bcrx ,Bcrx ,Medical ,09058v10 ,Ratings ,Consensus ,